Medication injections for weight loss – such as Ozempic – can reduce the risk of obesity-related cancers by as much as 50%. This is the conclusion of a new, large-scale study presented today at a scientific conference in Spain. “This is big news,” said Professor and Internist Liesbeth van Rossum (Erasmus MC) in Nieuws en Co. “The effect of this medication goes far beyond just suppressing appetite or losing weight.”

Lower Cancer Risk – Even More Than with Bariatric Surgery
Although Ozempic was originally developed for people with diabetes, the study shows that it also offers protection against cancer. Remarkably, the effect was even greater than in people who underwent weight-loss surgery. According to Van Rossum, this is because the medications also have anti-inflammatory and hormonal effects.
Medication Works More Broadly Than Expected
The study compared two groups: people who had bariatric surgery and those who received injectable medication. Initially, the surgery group lost more weight. However, it has now become clear that the cancer risk declined significantly more in the medication group – even when using older, less potent versions of today’s GLP-1 treatments.

Government and Patients Must Take Obesity More Seriously
Whether such medication will be used preventively in the future for people without obesity remains unclear. However, Van Rossum emphasizes that excess weight poses a serious health risk and requires active intervention. “Abdominal fat is not harmless. It doesn’t just increase the risk of diabetes but also of several types of cancer,” she warns.Her advice: don’t wait, take action.
More information can be found at checkoorzakenovergewicht.nl.
How Vi-Lifestyle Can Help
At Vi-Lifestyle, you’ll receive guidance from a medical team specialized in GLP-1 treatments like Ozempic and Wegovy. We combine medication with personalized coaching, lab testing, and lifestyle advice – all tailored to your individual needs. This way, we support not just weight loss, but long-term improvement of your overall health.